Health Care [ 3/12 ] | Biotechnology [ 13/73 ]
NYSE MKT | Common Stock
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.
The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis.
In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments.
CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer.
CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 25 | -2.33 Decreased by -1.57 K% | - |
| Feb 12, 25 | -0.10 Increased by +31.57% | -0.14 Increased by +31.57% |
| Dec 31, 24 | -2.70 Decreased by -1.59 K% | -0.10 Decreased by -2.60 K% |
| Aug 14, 24 | -0.14 Increased by +26.32% | -0.13 Decreased by -7.69% |
| May 15, 24 | -0.14 Increased by +26.32% | -0.14 |
| Feb 14, 24 | -0.14 Increased by +22.22% | -0.14 |
| Dec 21, 23 | -0.16 Increased by +23.81% | -0.16 |
| Aug 10, 23 | -0.19 Increased by +17.39% | -0.16 Decreased by -18.75% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -6.57 M Increased by +9.28% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -7.07 M Decreased by -5.42% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -6.11 M Increased by +19.94% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -6.86 M Increased by +18.06% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -7.24 M Increased by +14.86% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -6.71 M Increased by +14.57% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -7.63 M Increased by +14.31% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -8.37 M Increased by +20.66% | Decreased by N/A% Decreased by N/A% |